BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, Dessì M, Tanca FM, Sanna E, Deiana L, Panzone F, Contu P, Floris C. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008;24:305-13. [DOI: 10.1016/j.nut.2007.12.010] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Cao D, Wu G, Zhang B, Quan Y, Wei J, Jin H, Jiang Y, Yang Z. Resting energy expenditure and body composition in patients with newly detected cancer. Clinical Nutrition 2010;29:72-7. [DOI: 10.1016/j.clnu.2009.07.001] [Cited by in Crossref: 96] [Cited by in F6Publishing: 86] [Article Influence: 8.0] [Reference Citation Analysis]
2 Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Current Opinion in Supportive & Palliative Care 2009;3:269-75. [DOI: 10.1097/spc.0b013e328331124a] [Cited by in Crossref: 152] [Cited by in F6Publishing: 70] [Article Influence: 11.7] [Reference Citation Analysis]
3 Toledo M, Marmonti E, Massa D, Mola M, López-soriano FJ, Busquets S, Argilés JM. Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. e-SPEN Journal 2012;7:e135-8. [DOI: 10.1016/j.clnme.2012.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Rogers ES, MacLeod RD, Stewart J, Bird SP, Keogh JW. A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. BMC Cancer 2011;11:493. [PMID: 22111896 DOI: 10.1186/1471-2407-11-493] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
5 Berger AM, Mitchell SA, Jacobsen PB, Pirl WF. Screening, evaluation, and management of cancer-related fatigue: Ready for implementation to practice?: Cancer-Related Fatigue. CA: A Cancer Journal for Clinicians 2015;65:190-211. [DOI: 10.3322/caac.21268] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 12.6] [Reference Citation Analysis]
6 Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Dessì M, Panzone F, Contu P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010;15:200-11. [PMID: 20156909 DOI: 10.1634/theoncologist.2009-0153] [Cited by in Crossref: 119] [Cited by in F6Publishing: 104] [Article Influence: 9.9] [Reference Citation Analysis]
7 Cawood AL, Elia M, Stratton RJ. Systematic review and meta-analysis of the effects of high protein oral nutritional supplements. Ageing Res Rev 2012;11:278-96. [PMID: 22212388 DOI: 10.1016/j.arr.2011.12.008] [Cited by in Crossref: 221] [Cited by in F6Publishing: 181] [Article Influence: 20.1] [Reference Citation Analysis]
8 Silvério R, Laviano A, Rossi Fanelli F, Seelaender M. l-carnitine and cancer cachexia: Clinical and experimental aspects. J Cachexia Sarcopenia Muscle 2011;2:37-44. [PMID: 21475677 DOI: 10.1007/s13539-011-0017-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
9 Garcia JM, Shamliyan TA. Omega-3 Fatty Acids in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. Am J Med 2017;130:1151-5. [PMID: 29016347 DOI: 10.1016/j.amjmed.2017.03.066] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Fielitz J. Cancer cachexia-when proteasomal inhibition is not enough. J Cachexia Sarcopenia Muscle 2016;7:239-45. [PMID: 27386167 DOI: 10.1002/jcsm.12124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
11 Silvério R, Laviano A, Rossi Fanelli F, Seelaender M. L-Carnitine induces recovery of liver lipid metabolism in cancer cachexia. Amino Acids 2012;42:1783-92. [PMID: 21465256 DOI: 10.1007/s00726-011-0898-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
12 Mendes MC, Pimentel GD, Costa FO, Carvalheira JB. Molecular and neuroendocrine mechanisms of cancer cachexia. J Endocrinol 2015;226:R29-43. [PMID: 26112046 DOI: 10.1530/JOE-15-0170] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
13 Cheema UB, Most E, Eder K, Ringseis R. Effect of lifelong carnitine supplementation on plasma and tissue carnitine status, hepatic lipid metabolism and stress signalling pathways and skeletal muscle transcriptome in mice at advanced age. Br J Nutr 2019;121:1323-33. [DOI: 10.1017/s0007114519000709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Pagano G, Aiello Talamanca A, Castello G, Cordero MD, d'Ischia M, Gadaleta MN, Pallardó FV, Petrović S, Tiano L, Zatterale A. Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials. Int J Mol Sci 2014;15:20169-208. [PMID: 25380523 DOI: 10.3390/ijms151120169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
15 Tanca FM, Madeddu C, Macciò A, Serpe R, Panzone F, Antoni G, Massa E, Astara G, Mantovani G. New perspective on the nutritional approach to cancer-related anorexia/cachexia: preliminary results of a randomised phase III clinical trial with five different arms of treatment. Mediterr J Nutr Metab 2009;2:29-36. [DOI: 10.1007/s12349-009-0041-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Tuca Rodríguez A, Calsina-berna A, González-barboteo J, Gómez-batiste Alentorn X. Caquexia en cáncer. Medicina Clínica 2010;135:568-72. [DOI: 10.1016/j.medcli.2010.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;3:CD004310. [PMID: 23543530 DOI: 10.1002/14651858.cd004310.pub3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
18 Mantovani G, Madeddu C. Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia. Curr Opin Support Palliat Care 2008;2:275-81. [PMID: 19069312 DOI: 10.1097/spc.0b013e32830f47e4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
19 Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl). 2010;88:85-92. [PMID: 19802504 DOI: 10.1007/s00109-009-0547-z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 6.6] [Reference Citation Analysis]
20 Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, Pin F, Capdevila E, Madeddu C, López-Soriano FJ. L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr. 2012;31:889-895. [PMID: 22608917 DOI: 10.1016/j.clnu.2012.03.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
21 Hopkinson JB, Okamoto I, Addington-hall JM. What to eat when off treatment and living with involuntary weight loss and cancer: a systematic search and narrative review. Support Care Cancer 2011;19:1-17. [DOI: 10.1007/s00520-010-0964-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
22 Morley JE. Calories and cachexia. Curr Opin Clin Nutr Metab Care. 2009;12:607-610. [PMID: 19741513 DOI: 10.1097/mco.0b013e328331e9ce] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Dalal S, Bruera E. Cancer anorexia and cachexia. Supportive Oncology. Elsevier; 2011. pp. 150-63. [DOI: 10.1016/b978-1-4377-1015-1.00015-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Ries A, Trottenberg P, Elsner F, Stiel S, Haugen D, Kaasa S, Radbruch L. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med. 2012;26:294-304. [PMID: 21865295 DOI: 10.1177/0269216311418709] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]
25 Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28:2107-2118. [PMID: 28911059 DOI: 10.1093/annonc/mdx271] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 21.3] [Reference Citation Analysis]
26 Madeddu C, Mantovani G, Gramignano G, Macciò A. Advances in pharmacologic strategies for cancer cachexia. Expert Opin Pharmacother 2015;16:2163-77. [PMID: 26330024 DOI: 10.1517/14656566.2015.1079621] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
27 Adefisayo MA, Adeyemi WJ, Alabi QK. Combined but not single administration of vitamin C and l-carnitine ameliorates cisplatin-induced gastric mucosa damage in male rats. Can J Physiol Pharmacol 2018;96:830-8. [PMID: 29677454 DOI: 10.1139/cjpp-2017-0751] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Madeddu C, Mantovani G. An update on promising agents for the treatment of cancer cachexia. Curr Opin Support Palliat Care. 2009;3:258-262. [PMID: 19667995 DOI: 10.1097/spc.0b013e3283311c6f] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
29 Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol. 2010;11:107-117. [PMID: 21128029 DOI: 10.1007/s11864-010-0127-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
30 Balstad TR, Kaasa S, Solheim TS. Multimodal nutrition/anabolic therapy for wasting conditions: . Current Opinion in Clinical Nutrition and Metabolic Care 2014;17:226-35. [DOI: 10.1097/mco.0000000000000045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
31 Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88:625-636. [PMID: 23953794 DOI: 10.1016/j.critrevonc.2013.07.015] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
32 Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010;:CD006704. [PMID: 20614448 DOI: 10.1002/14651858.CD006704.pub3] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
33 Wang Z, Zhao C, Moya R, Davies JD. A novel role for CD4+ T cells in the control of cachexia. J Immunol 2008;181:4676-84. [PMID: 18802070 DOI: 10.4049/jimmunol.181.7.4676] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
34 Assi M, Derbré F, Lefeuvre-Orfila L, Rébillard A. Antioxidant supplementation accelerates cachexia development by promoting tumor growth in C26 tumor-bearing mice. Free Radic Biol Med 2016;91:204-14. [PMID: 26708754 DOI: 10.1016/j.freeradbiomed.2015.12.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
35 Donovan KA, Stein KD, Lee M, Leach CR, Ilozumba O, Jacobsen PB. Systematic review of the Multidimensional Fatigue Symptom Inventory-Short Form. Support Care Cancer 2015;23:191-212. [DOI: 10.1007/s00520-014-2389-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
36 Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev. 2012;CD008664. [PMID: 22513961 DOI: 10.1002/14651858.cd008664.pub2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
37 Rogers ES, Sasidharan R, Sequeira GM, Wood MR, Bird SP, Keogh JW, Arroll B, Stewart J, Macleod RD. A multi‐targeted treatment approach to cancer cachexia: Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) trial. JCSM Rapid Communications 2020;3:11-24. [DOI: 10.1002/rco2.10] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract. 2011;2011:601434. [PMID: 21760776 DOI: 10.1155/2011/601434] [Cited by in Crossref: 127] [Cited by in F6Publishing: 111] [Article Influence: 11.5] [Reference Citation Analysis]
39 Polly P, Tan TC. The role of vitamin D in skeletal and cardiac muscle function. Front Physiol 2014;5:145. [PMID: 24782788 DOI: 10.3389/fphys.2014.00145] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
40 Madeddu C, Macciò A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opinion on Pharmacotherapy 2009;10:1359-66. [DOI: 10.1517/14656560902960162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
41 Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer. 2010;18:1-9. [PMID: 19688225 DOI: 10.1007/s00520-009-0722-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
42 Ringseis R, Keller J, Eder K. Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Eur J Nutr 2013;52:1421-42. [DOI: 10.1007/s00394-013-0511-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
43 Abolhassani M, Guais A, Sanders E, Campion F, Fichtner I, Bonte J, Baronzio G, Fiorentini G, Israël M, Schwartz L. Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice. Invest New Drugs 2012;30:1331-42. [DOI: 10.1007/s10637-011-9692-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
44 Tazi E, Errihani H. Treatment of cachexia in oncology. Indian J Palliat Care 2010;16:129-37. [PMID: 21218002 DOI: 10.4103/0973-1075.73644] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
45 Macciò A, Madeddu C, Panzone F, Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother 2009;10:693-703. [PMID: 19239402 DOI: 10.1517/14656560902758343] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
46 Tisdale MJ. Cancer cachexia: . Current Opinion in Gastroenterology 2010;26:146-51. [DOI: 10.1097/mog.0b013e3283347e77] [Cited by in Crossref: 127] [Cited by in F6Publishing: 53] [Article Influence: 10.6] [Reference Citation Analysis]
47 Harding SV, Rideout TC, Jones PJH. Evidence for Using Alpha-Lipoic Acid in Reducing Lipoprotein and Inflammatory Related Atherosclerotic Risk. Journal of Dietary Supplements 2012;9:116-27. [DOI: 10.3109/19390211.2012.683136] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
48 Griffin LE, Fausnacht DW, Tuzo JL, Addington AK, Racine KC, Zhang H, Hughes MD, England KM, Bruno RS, O'keefe SF, Neilson AP, Stewart AC. Flavanol supplementation protects against obesity-associated increases in systemic interleukin-6 levels without inhibiting body mass gain in mice fed a high-fat diet. Nutrition Research 2019;66:32-47. [DOI: 10.1016/j.nutres.2019.03.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Rohr UD, Li WW, Ziqiang H, Wainright W, Schindler AE. The effect of fermented soy (FSWW08) on blood hematology and cachexia in cancer patients. Horm Mol Biol Clin Investig 2012;12:407-18. [PMID: 25436700 DOI: 10.1515/hmbci-2012-0028] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Busquets S, Serpe R, Sirisi S, Toledo M, Coutinho J, Martínez R, Orpí M, López-soriano FJ, Argilés JM. Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. Clinical Nutrition 2010;29:733-7. [DOI: 10.1016/j.clnu.2010.06.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
51 Wu C, Zhu M, Lu Z, Zhang Y, Li L, Li N, Yin L, Wang H, Song W, Xu H. L-carnitine ameliorates the muscle wasting of cancer cachexia through the AKT/FOXO3a/MaFbx axis. Nutr Metab (Lond) 2021;18:98. [PMID: 34724970 DOI: 10.1186/s12986-021-00623-7] [Reference Citation Analysis]
52 Hübner J, Stoll C. [Complementary therapy in palliative medicine]. Internist (Berl) 2011;52:36-41. [PMID: 21181106 DOI: 10.1007/s00108-010-2691-5] [Reference Citation Analysis]
53 Hilmi M, Jouinot A, Burns R, Pigneur F, Mounier R, Gondin J, Neuzillet C, Goldwasser F. Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196:135-159. [PMID: 30521882 DOI: 10.1016/j.pharmthera.2018.12.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
54 Reid J, Donnelly M, Cantwell M, Cardwell CR, Mills M, Murray LJ, Reid J. Thalidomide for managing cancer cachexia. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd008664] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Crenn P. Nutrition chez le patient adulte atteint de cancer : orexigènes et autres médicaments anticachectisants. Nutrition Clinique et Métabolisme 2012;26:269-77. [DOI: 10.1016/j.nupar.2012.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]